The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study

Bone

Volumn 81, Issue , 2015, Pages 675-682

  van der Hoorn, Mariëlle M C ^a,b   Tett, Susan E ^a   de Vries, Oscar J ^c   Dobson, Annette J ^a   Peeters, G M E E Geeske ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Esomeprazole; Fractures; Omeprazole; Osteoporosis medication; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; AUSTRALIAN; COHORT ANALYSIS; CONTROLLED STUDY; DEFINED DAILY DOSE; DOSE RESPONSE; DRUG EFFECT; DRUG USE; FEMALE; FRACTURE; HIGH RISK PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; PRESCRIPTION; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; WOMEN'S HEALTH; AUSTRALIA; CHEMICALLY INDUCED; FRACTURES, BONE; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUSTRALIA; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; ESOMEPRAZOLE; FEMALE; FRACTURES, BONE; HUMANS; LONGITUDINAL STUDIES; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RABEPRAZOLE; RISK FACTORS;

EID: 84943605631     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.08.024     Document Type: Article

References (49)

1. McGowan B., Bennett K., Barry M. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice. Pharmacoepidemiol. Drug Saf. 2010, 19:763-769.
2. Targownik L.E., Lix L.M., Metge C.J., Prior H.J., Leung S., Leslie W.D. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008, 179:319-326.
3. Heidelbaugh J.J., Kim A.H., Chang R., Walker P.C. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther. Adv. Gastroenterol. 2012, 5:219-232.
4. Tett S.E., Sketris I., Cooke C., van Zanten S.V., Barozzi N. Differences in Utilisation of Gastroprotective Drugs Between 2001 and 2005 in Australia and Nova Scotia 2013, Canada, Pharmacoepidemiol Drug Saf.
5. Australian Department of Health & Ageing Tables of prescription volumes and government costs (expenditures) under the Pharmaceutical Benefits Scheme (PBS) http://www.pbs.gov.au/info/statistics/expenditure-and-prescriptions-30-06-2014.
6. Food and Drug Administration Proton pump inhibitors BPCA drug use review and duration of use analysis http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214657.pdf.
7. Kwok C.S., Yeong J.K.-Y., Loke Y.K. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011, 48:768-776.
8. Australian Department of Health & Ageing Proton pump inhibitor and possible fracture risk. Australian Adverse Drug Reaction Bulletin February 2009, vol. 28, No 1.
9. U.S.Food and Drug Administration (FDA) Possible fracture risk with high dose, long-term use of proton pump inhibitors http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm213377.htm.
10. Moberg L.M., Nilsson P.M., Samsioe G., Borgfeldt C. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas 2014, 78:310-315.
11. Targownik L.E., Lix L.M., Leung S., Leslie W.D. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010, 138:896-904.
12. Targownik L.E., Leslie W.D., Davison K.S., Goltzman D., Jamal S.A., Kreiger N., Josse R.G., Kaiser S.M., Kovacs C.S., Prior J.C., Zhou W. The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: a population-based from the Canadian multicentre osteoporosis study (CaMos). Am. J. Gastroenterol. 2012, 107:1361-1369. the CaMos Research G.
13. Gray S.L., LaCroix A.Z., Larson J., Robbins J., Cauley J.A., Manson J.E., Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch. Intern. Med. 2010, 170:765-771.
14. Yu E., Blackwell T., Ensrud K., Hillier T., Lane N., Orwoll E., Bauer D. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif. Tissue Int. 2008, 83:251-259.
15. Solomon D.H., Diem S.J., Ruppert K., Lian Y.J., Liu C.C., Wohlfart A., Greendale G.A., Finkelstein J.S. Bone Mineral Density Changes Among Women Initiating Proton Pump Inhibitors or H2 Receptor Antagonists: A SWAN Cohort Study. J. Bone Miner. Res. 2015, 30:232-239.
16. Maggio M., Lauretani F., Ceda G.P., De Vita F., Bondi G., Corsonello A., Cattabiani C., Lattanzio F., Ruggiero C., Nouvenne A., Meschi T., Bandinelli S., Ferrucci L. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 2013, 57:437-442.
17. Sharara A.I., El-Halabi M.M., Ghaith O.A., Habib R.H., Mansour N.M., Malli A., El Hajj-Fuleihan G. Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metab. Clin. Exp. 2013, 62:518-526.
18. Hansen K.E., Jones A.N., Lindstrom M.J., Davis L.A., Ziegler T.E., Penniston K.L., Alvig A.L., Shafer M.M. Do proton pump inhibitors decrease calcium absorption?. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2010, 25:2786-2795.
19. Wright M.J., Sullivan R.R., Gaffney-Stomberg E., Caseria D.M., O'Brien K.O., Proctor D.D., Simpson C.A., Kerstetter J.E., Insogna K.L. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2010, 25:2205-2211.
20. Lee C., Dobson A.J., Brown W.J., Bryson L., Byles J., Warner-Smith P., Young A.F. Cohort profile: the Australian longitudinal study on women's health. Int. J. Epidemiol. 2005, 34:987-991.
21. Australian Department of Health & Ageing Pharmaceutical Benefit Scheme (PBS) http://www.pbs.gov.au/.
22. Hollingworth S., Duncan E.L., Martin J.H. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol. Drug Saf. 2010, 19:1019-1024.
23. WHO Collaborating Centres for Drug Statistics Methodology WHO/ATC index http://www.whocc.no/atc_ddd_index/.
24. Peeters G.M., Tett S.E., Dobson A.J., Mishra G.D. Validity of self-reported osteoporosis in mid-age and older women. Osteoporos. Int. 2013, 24:917-927.
25. National Health and Medical Research Council Australian Alcohol Guidelines: Health Risks and Benefits October 2001, National Health and Medical Research Council, Canberra, (Endorsed).
26. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med. Care 1992, 30:473-483.
27. Brown W.J., Burton N.W., Marshall A.L., Miller Y.D. Reliability and validity of a modified self-administered version of the Active Australia physical activity survey in a sample of mid-age women. Aust. N. Z. J. Public Health 2008, 32:535-541.
28. Ishizaki Horai Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. 1999, 13:27-36.
29. Rabenda V., Nicolet D., Beaudart C., Bruyère O., Reginster J.Y. Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos. Int. 2013, 24:121-137.
30. Salai M., Somjen D., Gigi R., Yakobson O., Katzburg S., Dolkart O. Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study. J. Bone Joint Surg. 2013, 95-B:1575-1580.
31. Levesque L.E., Hanley J.A., Kezouh A., Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010, 340. (b5087-b5087).
32. Suissa S. Immortal time bias in pharmacoepidemiology. Am. J. Epidemiol. 2008, 167:492-499.
33. Wainwright S.A., Marshall L.M., Ensrud K.E., Cauley J.A., Black D.M., Hillier T.A., Hochberg M.C., Vogt M.T., Orwoll E.S. Hip fracture in women without osteoporosis. J. Clin. Endocrinol. Metabol. 2005, 90:2787-2793. Group ftSoOFR.
34. Itoh S., Sekino Y., Shinomiya K., Takeda S. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J. Bone Miner. Metab. 2013, 31:206-211.
35. Genant H.K., Engelke K., Prevrhal S. Advanced CT bone imaging in osteoporosis. Rheumatology 2008, 47:iv9-iv16.
36. Lewis J.R., Barre D., Zhu K., Ivey K.L., Lim E.M., Hughes J., Prince R.L. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J. Bone Miner. Res. 2014, 29:2489-2497.
37. Adams A.L., Black M.H., Zhang J.L., Shi J.M., Jacobsen S.J. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann. Epidemiol. 2014, 24:286-290.
38. Cea Soriano L., Ruigomez A., Johansson S., Garcia Rodriguez L.A. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy 2014, 34:570-581.
39. Kirchheiner J., Glatt S., Fuhr U., Klotz U., Meineke I., Seufferlein T., Brockmoller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur. J. Clin. Pharmacol. 2009, 65:19-31.
40. Bahtiri E., Islami H., Hoxha R., Qorraj-Bytyqi H., Rexhepi S., Hoti K., Thaçi K., Thaçi S., Karakulak Ç. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J. Bone Miner. Metab. 2015, 1-9.
41. Lam J.R., Schneider J.L., Zhao W., Corley D.A. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013, 310:2435-2442.
42. Agardh D., Björck S., Agardh C.-D., Lidfeldt J. Coeliac disease-specific tissue transglutaminase autoantibodies are associated with osteoporosis and related fractures in middle-aged women. Scand. J. Gastroenterol. 2009, 44:571-578.
43. Bailey R.L., van Wijngaarden J.P. The role of B-vitamins in bone health and disease in older adults. Curr. Osteoporos. Rep. 2015, 13:256-261.
44. Kriegsman D.M., Penninx B.W., van Eijk J.T., Boeke A.J., Deeg D.J. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients' self-reports and on determinants of inaccuracy. J. Clin. Epidemiol. 1996, 49:1407-1417.
45. Peeters G.M., Alshurafa M., Schaap L., de Vet H.C. Diagnostic accuracy of self-reported arthritis in the general adult population is acceptable. J. Clin. Epidemiol. 2015, 68:452-459.
46. McGowan B., Bennett K., Marry J., Walsh J.B., Casey M. Primary-care prescribing of anti-osteoporotic-type medications following hospitalisation for fractures. Eur. J. Clin. Pharmacol. 2011, 67:301-308.
47. Katz P.O., Gerson L.B., Vela M.F. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2013, 108:308-328.
48. Huang C., Cen C., Ding X., Zhang H., Wu L. Effects of calcitriol on bone mineral density in patients treated with esomeprazole. Pharm. Biol. 2014, 52:1341-1344.
49. Scheurlen M. Long-term use of proton pump inhibitors: who needs prophylaxis?. Internist (Berl.) 2013, 54:366-372.